<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055870</url>
  </required_header>
  <id_info>
    <org_study_id>045.GID.2017.D</org_study_id>
    <nct_id>NCT04055870</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy</brief_title>
  <official_title>Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided&#xD;
      liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical&#xD;
      Center (MDMC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided&#xD;
      liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical&#xD;
      Center (MDMC). This is a clinical quality improvement (CQI) initiative to evaluate outcomes&#xD;
      within our institution. The data collected will be used to inform new innovative ways to&#xD;
      improve EUS-guided liver biopsy with an ultimate goal of improving the quality of patient&#xD;
      care. The clinical outcomes of this patient population have not been previously&#xD;
      systematically reviewed in MDMC. Currently, the procedure in not being performed routinely at&#xD;
      Methodist Dallas Medical Center (MDMC). However, with new technical and physician expertise,&#xD;
      this option is now available at our institution. PI will evaluate the efficacy, safety, and&#xD;
      adequacy of EUS-guided liver biopsy in patients requiring histologic examination of their&#xD;
      liver at MDMC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of core biopsy</measure>
    <time_frame>9/1/2017 and 9/1/2019</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of portal tracts</measure>
    <time_frame>9/1/2017 and 9/1/2019</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic yield</measure>
    <time_frame>9/1/2017 and 9/1/2019</time_frame>
    <description>We will define an adequate specimen as one containing ≥11 portal tracts or measuring ≥20 mm cumulative core length.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Hepatic</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Undergone EUS-guided liver biopsy at MDMC</arm_group_label>
    <description>Undergone EUS-guided liver biopsy at MDMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-guided liver biopsy at MDMC</intervention_name>
    <description>Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.</description>
    <arm_group_label>Undergone EUS-guided liver biopsy at MDMC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Age 18 years or older and have undergone EUS-guided liver biopsy at MDMC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Undergone EUS-guided liver biopsy at MDMC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Below 18 years of age&#xD;
&#xD;
          -  Did not undergo EUS-guided liver biopsy at MDMC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prashant Kedia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Dallas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

